To hear about similar clinical trials, please enter your email below
Trial Title:
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
NCT ID:
NCT05520788
Condition:
Hepatocellular Carcinoma
Biliary Tract Cancer
Conditions: Official terms:
Biliary Tract Neoplasms
Conditions: Keywords:
Liver Neoplasms
Biliary Tract Neoplasms
NGS
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Other
Intervention:
Intervention type:
Genetic
Intervention name:
precise medicine
Description:
During screening stage, all patients should accept next-generation sequencing (NGS) test.
Arm group label:
Precise medicine
Summary:
Exploring the precise medicine of patients with primary hepatobiliary cancer. And
evaluate the efficacy and safety of individualized treatment regimens for primary
hepatobiliary cancer based on next-generation sequencing.
Detailed description:
The purpose of this study is to explore the precise treatment in hepatobiliary cancer
patients and evaluate drug efficacy, progression free and overall survival. This trial
study is based on genetic tests, then therapeutic target drugs are administered according
to the genetic test reports. Patients with genetic abnormalities (such as mutations,
amplifications, or translocations) may benefit from precise treatment which targets
particular genetic abnormality. The identifications of these genetic abnormalities may
help treat hepatobiliary cancer patients.
The genetic tests are performed for the eligible subjects in this study, then therapeutic
target drugs are administered according to the genetic test reports. While the precise
treatments, follow-ups are conducted to evaluate the efficacy and safety of the target
drugs for the subjects, until the overall survival.
Criteria for eligibility:
Study pop:
Patients diagnosed primary hepatobiliary cancer in Tongji Hospital, Wuhan with results of
NGS tests.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Age from 18 to 65, male or female.
2. Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV.
3. Palliative care as the preferred.
4. The result of next-generation sequencing (NGS) test show the patient has gene
mutation and also can be treated by the right commercial products that have been
approved by the China Food and Drug Administration (CFDA) or the Food and Drug
Administration (FDA).
5. ECOG performance status 0-2.
6. Life expectancy ≥3 months.
7. Agree to sign informed consent form.
Exclusion Criteria:
1. Hepatobiliary cancer patient with stageI-III, or with any of the following items
will not be eligible for screening. Such as, suitable for the treatment of radical
resection, radical resection but evaluation unmeasurable.
2. The result of NGS test show the patient has no gene mutation, or has gene mutation
but no medicine.
3. ECOG performance status ≥ 3.
4. Female patients who are pregnant or not using a contraceptive method of birth
control.
5. History or presence of serious cardiovascular or cerebrovascular abnormalities.
6. Abnormalities of the hepatic or renal functions, such as jaundice, ascites,
bilirubin ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3
(according to National Cancer Institute [NCI] Common Terminology Criteria for
Adverse Events [CTC-AE] v4.0), creatinine ratio > 3.5g/24 hours, renal failure.
7. Persistent infection > grade 2 (according to National Cancer Institute [NCI] Common
Terminology Criteria for Adverse Events [CTC-AE] v4.0).
8. Patient has underwent a major operation 4 weeks prior to screening or has not yet
recovered from the operation.
9. Patient with epilepsy, known or untreated brain metastases.
10. The presence of wounds, ulcers or fractures that can not be healed, or with a past
history of transplantation.
11. The presence of bleeding events ≥grade 3 (according to National Cancer Institute
[NCI] Common Terminology Criteria for Adverse Events [CTC-AE] v4.0) , present
evidence or past history of coagulation dysfunction disorders.
12. Known human immunodeficiency virus (HIV) infection history.
13. Patient with drug abuse or unstable compliance.
14. The presence of unresolved toxicity caused by any previous treatment/operation >
grade 1 (according to National Cancer Institute [NCI] Common Terminology Criteria
for Adverse Events [CTC-AE] v4.0), except alopecia, anemia or hypothyroidism).
15. Investigator consider that the patient should not be enrolled in this study by
careful assessment.
16. The subjects participate in any other clinical trial in the meantime.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
Address:
City:
Wuhan
Zip:
430030
Country:
China
Status:
Recruiting
Contact:
Last name:
Ze-yang Ding, M.D.
Phone:
+8613407156200
Email:
dingzyang@sina.com
Start date:
May 1, 2020
Completion date:
December 31, 2025
Lead sponsor:
Agency:
Tongji Hospital
Agency class:
Other
Source:
Tongji Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05520788